Annual Accounts Receivable
$114.83 M
+$10.62 M+10.19%
31 December 2023
Summary:
10x Genomics annual accounts receivable is currently $114.83 million, with the most recent change of +$10.62 million (+10.19%) on 31 December 2023. During the last 3 years, it has risen by +$29.58 million (+34.69%). TXG annual accounts receivable is now at all-time high.TXG Accounts Receivable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Accounts Receivable
$83.53 M
-$7.65 M-8.39%
30 September 2024
Summary:
10x Genomics quarterly accounts receivable is currently $83.53 million, with the most recent change of -$7.65 million (-8.39%) on 30 September 2024. Over the past year, it has dropped by -$31.31 million (-27.26%). TXG quarterly accounts receivable is now -82.63% below its all-time high of $480.74 million, reached on 01 March 2016.TXG Quarterly Accounts Receivable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TXG Accounts Receivable Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | - | -27.3% |
| 3 y3 years | +34.7% | -2.0% |
| 5 y5 years | +244.1% | +150.3% |
TXG Accounts Receivable High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | at high | +34.7% | -27.3% | +9.6% |
| 5 y | 5 years | at high | +244.1% | -27.3% | +267.5% |
| alltime | all time | at high | +760.8% | -82.6% | +267.5% |
10x Genomics Accounts Receivable History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | - | $83.53 M(-8.4%) |
| June 2024 | - | $91.18 M(-0.1%) |
| Mar 2024 | - | $91.31 M(-20.5%) |
| Dec 2023 | $114.83 M(+10.2%) | $114.83 M(+10.6%) |
| Sept 2023 | - | $103.85 M(+18.4%) |
| June 2023 | - | $87.69 M(+12.5%) |
| Mar 2023 | - | $77.94 M(-25.2%) |
| Dec 2022 | $104.21 M(+22.2%) | $104.21 M(+24.7%) |
| Sept 2022 | - | $83.55 M(+9.6%) |
| June 2022 | - | $76.20 M(-0.4%) |
| Mar 2022 | - | $76.53 M(-10.2%) |
| Dec 2021 | $85.25 M(+66.5%) | $85.25 M(+8.7%) |
| Sept 2021 | - | $78.43 M(+31.4%) |
| June 2021 | - | $59.68 M(+4.0%) |
| Mar 2021 | - | $57.41 M(+12.1%) |
| Dec 2020 | $51.21 M | $51.21 M(+42.1%) |
| Sept 2020 | - | $36.03 M(+58.5%) |
| Date | Annual | Quarterly |
|---|---|---|
| June 2020 | - | $22.73 M(-26.3%) |
| Mar 2020 | - | $30.85 M(-7.6%) |
| Dec 2019 | $33.37 M(+18.8%) | $33.37 M(+27.6%) |
| Sept 2019 | - | $26.15 M(-2.4%) |
| June 2019 | - | $26.80 M(-4.6%) |
| Dec 2018 | $28.09 M(+110.5%) | $28.09 M(-94.1%) |
| Dec 2017 | $13.34 M | - |
| Sept 2017 | - | $480.03 M(+2.1%) |
| June 2017 | - | $470.13 M(-2.1%) |
| Mar 2017 | - | $480.17 M(+7.0%) |
| Dec 2016 | - | $448.58 M(+5.8%) |
| Sept 2016 | - | $424.00 M(-0.7%) |
| June 2016 | - | $427.06 M(-11.2%) |
| Mar 2016 | - | $480.74 M(+2.3%) |
| Dec 2015 | - | $470.12 M(+24.2%) |
| Sept 2015 | - | $378.41 M(-12.8%) |
| Mar 2015 | - | $433.74 M |
FAQ
- What is 10x Genomics annual accounts receivable?
- What is the all time high annual accounts receivable for 10x Genomics?
- What is 10x Genomics quarterly accounts receivable?
- What is the all time high quarterly accounts receivable for 10x Genomics?
- What is 10x Genomics quarterly accounts receivable year-on-year change?
What is 10x Genomics annual accounts receivable?
The current annual accounts receivable of TXG is $114.83 M
What is the all time high annual accounts receivable for 10x Genomics?
10x Genomics all-time high annual accounts receivable is $114.83 M
What is 10x Genomics quarterly accounts receivable?
The current quarterly accounts receivable of TXG is $83.53 M
What is the all time high quarterly accounts receivable for 10x Genomics?
10x Genomics all-time high quarterly accounts receivable is $480.74 M
What is 10x Genomics quarterly accounts receivable year-on-year change?
Over the past year, TXG quarterly accounts receivable has changed by -$31.31 M (-27.26%)